Table 7 Randomized controlled clinical trials in individuals with migraine comparing a monoclonal antibody targeting the CGRP pathway with another migraine preventive agent
Trial | Phase | Monoclonal antiboy/dose | Comparator/dose | Duration | № of participants |
|---|---|---|---|---|---|
HER-MES [14] | III | Erenumab 70-140 mg (m) | Topiramate 50-100 mg (d) | 12 weeks | 777 |